The share repurchase programme runs as from 5 February 2026 and up to and including 29 January 2027 at the latest. In this period, Jyske Bank will acquire shares with a value of up to DKK 3 billion, cf. Corporate Announcement No. 11/2026 of 5 February 2026. The share repurchase programme is initiated and structured in compliance with the Market Abuse Regulation (Regulation (EU) No 596/2014) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (together with the Market Abuse Regulation, the “Safe Harbour Rules”). The following transactions have been made under the program:  Number of shares Average purchase price (DKK) Transaction value (DKK)Accumulated, previous announcement 1,916,299 941.89 1,804,942,9137 September 2026 10,491 1.101.07 11,551,3398 September 2026 10,529 1.093.86 11,517,3029 September 2026 10,954 1.083.08 11,864,00710...

Sampo plc, stock exchange release, 14 September 2026 at 8:30 am EEST Sampo plc’s share buybacks week 37/2026 During week 37 (7 September 2026 – 11 September 2026), Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI4000552500) as follows:Market (MIC Code) Daily volume (in number of shares) and weighted average price of the purchased shares, EUR* Aggregated weekly volume (in number of shares) and weighted weekly average price of the purchased shares, EUR*    07/09/2026 08/09/2026 09/09/2026 10/09/2026 11/09/2026 Week 37/2026, totalAQEU Volume 25,371 80,848 81,065 52,551 561 240,396Average price 9.63 9.53 9.38 9.42 9.45 9.47CEUX Volume 283,865 283,196 274,328 262,471 119,209 1,223,069Average price 9.66 9.55 9.45 9.45 9.46 9.52TQEX Volume 41,668 39,642 38,696 36,347 29,489 185,842Average...

Allschwil, Switzerland, September 14, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that its partner Asahi Kasei Therapeutics Corp. started a phase 2 clinical study in Japan with the antifungal Cresemba® (isavuconazole) for pediatric patients at risk of deep mycoses. Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: “We are very pleased with the start of the pediatric study for Cresemba by our partner Asahi Kasei Therapeutics Corp. Invasive fungal infections pose a critical threat for children suffering from hematologic malignancies or immunodeficiency disorders. Despite this high-risk setting, treatment options remain limited. Making Cresemba available to pediatric patients...

Secured a substantial order to supply gas compression systems for the Cloud Connector Pipeline project Awarded a major order for a modular liquefaction solution supporting Plaquemines LNG facility expansion Awards deepen long-standing strategic collaboration with Venture GlobalHOUSTON and LONDON, Sept. 13, 2026 (GLOBE NEWSWIRE) — Baker Hughes (NASDAQ: BKR) and Venture Global LNG are expanding their long-standing collaboration to advance critical U.S. gas infrastructure. Reinforcing Baker Hughes’ connected capabilities across the natural gas value chain, the company will provide gas compression systems for the Cloud Connector Pipeline project in Louisiana, as well as a modular liquefaction solution including cold boxes to support the expansion of the Plaquemines LNG facility. Together, the pipeline and liquefaction awards demonstrate...

Agreement brings delayed and real-time OTC Link pricing to CITIC Securities Brokerage (HK) Limited’s Hong Kong clients through its trading platforms NEW YORK, Sept. 13, 2026 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced a market data licensing agreement with CITIC Securities Brokerage (HK) Limited, a subsidiary of CITIC Securities International, the international arm of CITIC Securities. Under the agreement, CITIC Securities Brokerage (HK) Limited will distribute OTC Markets pricing data to clients through its browser-based trading platform and mobile application. Delayed Level 1 quote data from OTC Link ATS, OTC Markets’ primary trading venue for US OTC equity securities, will be available on a 15-minute delayed basis...

The Board of Directors of Kvika banki has appointed Jón Birgir Jónsson as Chief Executive Officer of Kvika banki. Jón Birgir will assume his new role on 1 December 2026, succeeding Ármann Þorvaldsson, who announced earlier this year his intention to step down as CEO. Jón Birgir brings extensive experience from international financial markets, having spent most of his career in London and New York with two leading global asset management firms. From 2013 to 2025, Jón Birgir was with Neuberger Berman in London, where he was a Partner and held a senior management role. He joined the firm to strengthen its global fixed income capabilities and subsequently took on broader responsibilities, including the management of relationships with professional and institutional investors. Prior to joining Neuberger Berman, he worked at J.P. Morgan Asset...

Company Announcement Copenhagen, 13 September 2026No. 57/2026 NEW MID-TERM FINANCIAL TARGETS – ISS TO ACCELERATE HIGHER-QUALITY GROWTH AND EXPAND MARGINS ISS A/S, a global leader in workplace experience and facility services, today announces new mid-term financial targets for 2026-2028 to be presented at the Capital Markets Day tomorrow. ISS A/S is targeting the following new mid-term financial targets for 2026-2028 (replacing targets announced in November 2022):Average annual organic growth above 5%, measured over the period 2026-2028   Operating margin1) between 5.5-6.0% in 2028 Cash conversion of above 60%Like-for-like growth (volume growth and net new wins) is expected to contribute a larger share of organic growth going forward, while price increases are expected to represent a reduced share of growth compared to 2026 levels....

Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%, while achieving an objective response rate of 59.1% vs 9.7%1 The novel B7-H3-targeted antibody-drug conjugate with a dual release mechanism of the payload is based on MediLink’s proprietary TMALIN® platform, designed to maximise antitumour activity while minimising off-target toxicity2,3 Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong, and Macau across multiple tumour types, with plans to rapidly initiate global trials Tam-Peli has received U.S. FDA and China CDE Breakthrough Therapy Designations for relapsed small-cell lung cancer (SCLC)Basel, 13 September 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY)...